Collaboration is a key value at the heart of OICR.

Collaboration is an integral driver of our leadership team, which brings together experts with diverse voices, backgrounds and skill sets to lead our shared pursuit of world-class translational cancer research together. OICR is overseen by a volunteer Board of Directors, which is responsible for the success and sustainability of the Institute and the overall governance of the affairs of the corporation.

OICR has joined the 50 – 30 Challenge. This is a challenge to increase the representation and inclusion of diverse groups within the workplace

Scientific Advisory Board
Richard L. Schilsky, MD, FASCO (Chair)
  • Former Senior Vice President and Chief Medical Officer, American Society of Clinical Oncology
Ewan Birney, PhD
  • Director and Joint Head of Research and Senior Scientist, European Bioinformatics Institute (EMBL-EBI)
Hakim Djaballah, PhD
  • President and CEO, Keren Therapeutics
Olivera J. Finn, PhD
  • Chair and Professor, Department of Immunology
    University of Pittsburgh School of Medicine
  • Director, Immunology Program
    University of Pittsburgh Cancer Institute
Funda Meric-Bernstam, MD
  • Department of Investigational Cancer Therapeutics,
    Division of Cancer Medicine
    MD Anderson Cancer Center
Edward F. Patz, MD
  • James and Alice Chen Distinguished Professor of Radiology
    Professor of Radiology
    Professor in Pathology
    Professor in Pharmacology & Cancer Biology
    Member of the Duke Cancer Institute
Sylvia K. Plevritis, PhD
  • Professor and Chair
    Department of Biomedical Data Science


Deborah Schrag, MD, MPH
  • Chair of the Department of Medicine
    Memorial Sloan Kettering Cancer Center